

Abstract

The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S_1 is hydrogen, halogen, alkyl (1-3C), CN, CF_3 , OCF_3 , SCF_3 , alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR_3 , S, CH_2 , O, SO or SO_2 , wherein R_3 is H or alkyl (1-3C);.....Z represents =C or -N; $-R_1$ and R_2 independently represent H or alkyl (1-3C), or R_1 and R_2 together can form a bridge of 2 or 3 C-atoms; R_4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl - methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D_2 -receptor agonism and partial serotonin 5-HT_{1A}-receptor agonism mediated activities.

